Market News & Analysis
FTSE lower on RBS, NMC and AstraZeneca
Fiona Cincotta February 14, 2020 8:42 PM
Negative company news is dragging down the FTSE even as the Chinese virus outbreak is showing signs of containment.
Royal Bank of Scotland lost 5.4% in early trading after the majority state-owned banking group reported an increased profit for the fourth quarter but reduced its medium-term returns target. Shares in the embattled health operator NMC Health also dropped after the vice chair Khalifa Butti Omeir Bin Yousef resigned from his position, only days after the company’s co-founder B.R. Shetty left the board after admitting to potentially inaccurately reporting his holdings in the company. AstraZeneca also took a hit in its share price having reported a drop in core operating profits and missing expectations.
Brent crude steadies as Russia decision expected
The slide in Brent crude prices has stopped for the moment and prices seem to have stabilised just above the $56/bbl mark thanks to the slowdown of the spread of the coronavirus in China. A large part of China’s industrial production has come back on line this week or is due to restart over the next three days after several weeks of closures. OPEC and Russia have yet to come to some agreement over whether the extended producer group will increase its existing production cuts to counter the decline in oil prices. Russia is dragging its feet and even a meeting between the country’s energy minister and main oil producers has not yielded an answer to OPEC’s proposal to reign in production by another 600,000bbl/d. WTI is also marginally higher, trading close to $51.50.
The pound perked up overnight at the prospect of higher government spending under the new Chancellor of the Exchequer but has since given up about 0.1% against the dollar, settling just above the $1.3 mark.
From time to time, GAIN Capital Australia Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.
As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.